Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Mylan Scores IPR Victory, Paving The Way For Follow-On Lantus

Dec 13 2018

• By Jessica Merrill

insulin word on checkered paper sheet- vector illustration - Vector

Related Content

Merck Steps Out Of Insulin Glargine Market, But Says It Remains Committed To Biosimilars

Oct 11 2018

Inter Partes Patent Challenges Are Constitutional, US Supreme Court Rules

Apr 25 2018

Keeping Track: Mylan Wins First US FDA Approval For Neulasta Biosimilar, But Lands A CRL For Insulin Glargine; Genentech Nabs Broad Full Approval For Venclexta, PV Indication For Rituxan

Jun 08 2018

US FDA's Gottlieb Shuts The Door On Exclusivity For 'Transition' Biologics

Dec 11 2018

When Drugs Become Biologics: US FDA Guidances Explain 'Transition Provisions'

Dec 11 2018

GMP Lapses At Biocon’s Indian Site – Jitters for Neulasta Biosimilar Plans?

May 04 2018

Sanofi-Lilly Settlement Paves Way For Biosimilar Lantus

Sep 29 2015

Related Companies

Viatris Inc.

Sanofi

Eli Lilly and Company

Merck & Co., Inc.

Novo Nordisk A/S

Biocon, Ltd.

Additional Topics

United States Biosimilars Intellectual Property Commercial Generic Drugs Regulation Policy Legal Issues Metabolic Disorders BioPharmaceutical

More from Biosimilars

More from Biosimilars & Generics

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window